Novartis Slumps 11% After Trial Failure Scrutinizes M&A Strategy

Novartis shares slumped 11% in a single session this week, wiping nearly $30 billion off its market value and erasing all year-to-date gains after the late-stage clinical trial failure of the muscle-wasting disorder drug del-desiran, according to a Yahoo Finance report. The sharp sell-off has intensified investor scrutiny surrounding the pharmaceutical giant's aggressive deal-making strategy and multi-billion-dollar expenditure on external assets.

"It's going to take a while for confidence to return," said Gillian Hollenstein, lead manager at Point Capital Navigator Fund, adding: "They would have been better off doing some more smaller acquisitions, bolt-on ones rather than trying to hit it out of the park."

Multi-Billion-Dollar Deal Making Under Review

The setback places CEO Vas Narasimhan's capital allocation track record under a harsh spotlight. Over the past three years, Narasimhan has committed more than $30 billion toward corporate acquisitions and strategic partnerships to bolster the drugmaker's pipeline, highlighted by last year's $12 billion purchase of Avidity, which brought del-desiran into the portfolio.

The failure of del-desiran to meet its primary endpoints in late-stage testing directly challenges the premise of these large-scale investments. Pharmaceutical companies routinely rely on major acquisitions to replace revenue streams lost to patent expirations on legacy blockbuster medications, but high-profile clinical failures expose shareholders to immediate downside volatility when expensive pipeline bets collapse.

Shareholder Pressure and Board Oversight

In the wake of the market drop, major institutional investors have begun demanding structural and strategic adjustments. Artisan Partners, a significant shareholder in Novartis, called for a formal board shake-up to strengthen governance and M&A oversight, while maintaining its backing of CEO Vas Narasimhan.

Market participants note that future capital deployment will face heightened skepticism. Larger transactions will likely be assessed carefully by investors considering the mixed market reception to several prior deals.

"Larger transactions will likely be assessed carefully by investors considering the mixed market reception to several prior deals," said Michael Hannig, portfolio manager at DJE Kapital.

What Is at Stake for Drug Developers

The market reaction underscores the delicate balance pharmaceutical executives must maintain between internal research and external business development. As development costs rise and regulatory hurdles tighten, large-cap drugmakers face continuous pressure from institutional holders to demonstrate strict discipline in evaluating acquisition targets rather than pursuing high-risk, megadeal expansions.